For laboratory research use only. Not for human or veterinary use. Read our research-use policy

GLP-1 research

Tirzepatide research peptide

A 39-amino-acid fatty-diacid-modified peptide that agonises the GIP and GLP-1 receptors (development code LY3298176).

9 sizes · from $16.99 · 4 in stock · flat $24.95 US shipping per order

Sizes, prices and availability

Tirzepatide sizes and prices
SizeSKUStated purityBatch COAPriceAvailability
5 mg TR5 Not yet provided Not yet provided $16.99 Out of stock
10 mg TR10 Not yet provided Not yet provided $19.99 In stock
15 mg TR15 Not yet provided Not yet provided $21.99 Out of stock
20 mg TR20 Not yet provided Not yet provided $24.99 In stock
30 mg TR30 Not yet provided Not yet provided $30.99 In stock
40 mg TR40 Not yet provided Not yet provided $36.99 Out of stock
50 mg TR50 Not yet provided Not yet provided $44.99 Out of stock
60 mg TR60 Not yet provided Not yet provided $53.99 In stock
100 mg TR100 Not yet provided Not yet provided $72.99 Out of stock

Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details

About Tirzepatide

Tirzepatide (development code LY3298176) is a dual agonist of the GIP receptor and the GLP-1 receptor. It is a synthetic 39-amino-acid peptide with a fatty diacid side chain that supports binding to serum albumin.

A 2020 JCI Insight study found a greater degree of receptor engagement for the GIP receptor than for the GLP-1 receptor (an imbalanced agonist) and reported that at the GLP-1 receptor tirzepatide is biased toward cAMP generation over beta-arrestin recruitment, with weaker receptor internalisation than native GLP-1.

What the published literature covers

  • Willard et al. (2020) describe tirzepatide as mimicking native GIP at the GIP receptor while showing signalling bias at the GLP-1 receptor.
  • In primary islet experiments in the same study, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, which the authors link to the biased signalling of tirzepatide.
  • Large clinical trial reports (SURPASS and SURMOUNT programmes) are available in the New England Journal of Medicine; two are listed below.

Vial arithmetic for Tirzepatide

Work out the concentration, syringe units per draw and draws per vial for any Tirzepatide vial size with our Tirzepatide reconstitution calculator, or the general peptide reconstitution calculator. To turn a volume into syringe units, use the syringe units converter. These tools do arithmetic only; they do not suggest any amount.

FAQ

Which receptors does tirzepatide act on?

Tirzepatide is a dual agonist of the GIP receptor and the GLP-1 receptor.

Is tirzepatide the same as semaglutide?

No. Semaglutide is a GLP-1 receptor agonist derived from the GLP-1 sequence, while tirzepatide is a dual GIP and GLP-1 receptor agonist. They are different molecules with different formulas.

What is the molecular formula of tirzepatide?

PubChem lists tirzepatide as C225H348N48O68 with a molecular weight of about 4813 g/mol.

What sizes of Tirzepatide does Covalume list?

Covalume lists Tirzepatide in 9 sizes: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 100 mg. Each size shows its price and live stock status in the variants table on this page.

How is the purity of Tirzepatide documented?

Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.

References

  1. Willard FS, Douros JD, Gabe MB, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5. PubMed 32730231 · DOI
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387:205-216. PubMed 35658024 · DOI
  3. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385:503-515. PubMed 34170647 · DOI

Identity values are from PubChem (CID 166567236) and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-18.

Related research peptides

From the research library